Can a second stop be successful? nilotinib trial for CML relapse
NCT ID NCT02917720
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether taking nilotinib for two years can help people with chronic myeloid leukemia (CML) stay in remission after stopping their medication a second or third time. About 75 adults who previously tried and failed to stop treatment will take nilotinib and then attempt to stop again. The goal is to see if they can maintain a deep molecular remission for at least 12 months without restarting therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nilotinib
What this could lead to
If successful, this could offer a way for CML patients who relapsed after stopping treatment to safely stop again and remain in remission.
What could go wrong
This is a small Phase 2 trial with only 75 participants, so results may not apply to everyone. The treatment requires two years of nilotinib, and some patients may still relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, locatie VUmc
Amsterdam, 1081 HV, Netherlands
-
Kliniken Ostalb, Stauferklinikum Schwäbisch Gmünd
Mutlangen, 73557, Germany
-
Klinikum Bayreuth
Bayreuth, 95445, Germany
-
Klinikum Chemnitz
Chemnitz, 09113, Germany
-
Klinikum der Philipps-Universität
Marburg, 35033, Germany
-
Klinikum rechts der Isar
München, Bavaria, 81675, Germany
-
Medizinische Hochschule Hannover
Hannover, North Rhine-Westphalia, 30625, Germany
-
Onkologische Schwerpunktpraxis
Esslingen am Neckar, 73728, Germany
-
Schwarzwald-Baar Klinikum
Villingen-Schwenningen, 78052, Germany
-
Schwerpunktpraxis Onkologie
Heilbronn, 74072, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79108, Germany
-
Universitätsklinikum Halle (Saale)
Halle, Germany
-
Universitätsklinikum Rostock
Rostock, 18057, Germany
-
Universitätsklinikum der RWTH
Aachen, 52074, Germany
-
Universitätsmedizin Mannheim
Mannheim, Baden-Wurttemberg, 68167, Germany